- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
Carisma is building a pipeline with an initial focus in oncology aiming to bring the power of cellular immunotherapy to the large number of solid tumor patients in whom other approaches fail. At the start of 2021, Carisma initiated the first ever clinical study of a CAR-Macrophage therapy for patients, achieving a key milestone in the development of this new therapeutic approach, and giving hope to patients living with cancer. In Q4 2023, Carisma initiated the first ever clinical study of a CAR-Monocyte in the solid tumor setting.
| Current Portfolio | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
CT – 0525 (CAR-Monoctye)Discovery | Preclinical | Phase 1 |
|||
CT – 0508 (CAR-Macrophage)Discovery | Preclinical | Phase 1 |
|||
CT – 1119 (CAR-Monocyte)Discovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: Solid Tumor AntigenDiscovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: Additional TargetsDiscovery | Preclinical | Phase 1 |
|||
Fibrosis and ImmunologyDiscovery | Preclinical | Phase 1 |
Carisma is developing CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. CT-0525 is in Phase 1 clinical development.
CT-0508 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. CT-0508 is in Phase 1 clinical development both as a monotherapy and in combination with pembrolizumab, an anti-PD1 therapy. Given its decision to prioritize CT-0525 as the product candidate in its HER2 program, Carisma has ceased further development of CT-0508 and new patients will no longer be enrolled in the Phase 1 clinical trial.
CT-1119 is an ex vivo gene-modified autologous CAR-Monocyte cellular therapy to target mesothelin-positive solid tumors. Development of CT-1119 is currently paused, pending additional financing.
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. In December 2023, Carisma announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. Five targets have been nominated (including the lead), with the option to identify an additional 7 oncology targets.
Using our macrophage and monocyte ex vivo and in vivo engineering platform, Carisma is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology. Carisma’s current lead focus outside of oncology is in liver fibrosis.
Carisma’s scientists are expanding the functionality of engineered macrophages to increase the number of patients that can potentially benefit from this transformative technology. With research programs targeting liver fibrosis, neurodegeneration and autoimmune disorders, Carisma is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
Liver fibrosisDiscovery | Preclinical | Phase 1 |
|||
Autoimmune diseasesDiscovery | Preclinical | Phase 1 |
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Carisma newsroom.
We have decades of experience in the industry, and are working to a develop a new approach to cell therapies.
Get to know the team committed to developing innovative treatments for patients.
Our Team